Literature DB >> 22753931

Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells.

Chun Jing Wang1, Rupert Kenefeck, Lukasz Wardzinski, Kesley Attridge, Claire Manzotti, Emily M Schmidt, Omar S Qureshi, David M Sansom, Lucy S K Walker.   

Abstract

The CTLA-4 pathway is a key regulator of T cell activation and a critical failsafe against autoimmunity. Although early models postulated that CTLA-4 transduced a negative signal, in vivo evidence suggests that CTLA-4 functions in a cell-extrinsic manner. That multiple cell-intrinsic mechanisms have been attributed to CTLA-4, yet its function in vivo appears to be cell-extrinsic, has been an ongoing paradox in the field. Although CTLA-4 expressed on conventional T cells (Tconv) can mediate inhibitory function, it is unclear why this fails to manifest as an intrinsic effect. In this study, we show that Tconv-expressed CTLA-4 can function in a cell-extrinsic manner in vivo. CTLA-4(+/+) T cells, from DO11/rag(-/-) mice that lack regulatory T cells, were able to regulate the response of CTLA-4(-/-) T cells in cotransfer experiments. This observation provides a potential resolution to the above paradox and suggests CTLA-4 function on both Tconv and regulatory T cells can be achieved through cell-extrinsic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22753931      PMCID: PMC3442233          DOI: 10.4049/jimmunol.1200972

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Phenotypic analysis of CTLA-4 and CD28 expression during transient peptide-induced T cell activation in vivo.

Authors:  B Metzler; C Burkhart; D C Wraith
Journal:  Int Immunol       Date:  1999-05       Impact factor: 4.823

Review 2.  The emerging role of CTLA-4 as an immune attenuator.

Authors:  C B Thompson; J P Allison
Journal:  Immunity       Date:  1997-10       Impact factor: 31.745

3.  Normal responsiveness of CTLA-4-deficient anti-viral cytotoxic T cells.

Authors:  M F Bachmann; P Waterhouse; D E Speiser; K McKall-Faienza; T W Mak; P S Ohashi
Journal:  J Immunol       Date:  1998-01-01       Impact factor: 5.422

4.  CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice.

Authors:  E A Tivol; S D Boyd; S McKeon; F Borriello; P Nickerson; T B Strom; A H Sharpe
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

5.  Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity.

Authors:  Dirk Homann; Wolfgang Dummer; Tom Wolfe; Evelyn Rodrigo; Argyrios N Theofilopoulos; Michael B A Oldstone; Matthias G von Herrath
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous.

Authors:  M F Bachmann; G Köhler; B Ecabert; T W Mak; M Kopf
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

7.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

8.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

9.  B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).

Authors:  D A Mandelbrot; A J McAdam; A H Sharpe
Journal:  J Exp Med       Date:  1999-01-18       Impact factor: 14.307

10.  CTLA-4 ligation blocks CD28-dependent T cell activation.

Authors:  T L Walunas; C Y Bakker; J A Bluestone
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

View more
  43 in total

1.  Impact of selective CD28 blockade on virus-specific immunity to a murine Epstein-Barr virus homolog.

Authors:  Rebecca L Crepeau; Joseph A Elengickal; Glenn M La Muraglia; Mandy L Ford
Journal:  Am J Transplant       Date:  2019-03-29       Impact factor: 8.086

Review 2.  T-cell costimulatory blockade in organ transplantation.

Authors:  Jonathan S Maltzman; Laurence A Turka
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

Review 3.  Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?

Authors:  Franck Carbonnel; Emilie Soularue; Clélia Coutzac; Nathalie Chaput; Christine Mateus; Patricia Lepage; Caroline Robert
Journal:  Semin Immunopathol       Date:  2017-01-16       Impact factor: 9.623

4.  Surface expression of inhibitory (CTLA-4) and stimulatory (OX40) receptors by CD4+ regulatory T cell subsets circulating in human malaria.

Authors:  Raquel M Gonçalves-Lopes; Nathália F Lima; Karina I Carvalho; Kézia K G Scopel; Esper G Kallás; Marcelo U Ferreira
Journal:  Microbes Infect       Date:  2016-06-16       Impact factor: 2.700

5.  Selective CD28 blockade attenuates CTLA-4-dependent CD8+ memory T cell effector function and prolongs graft survival.

Authors:  Danya Liu; I Raul Badell; Mandy L Ford
Journal:  JCI Insight       Date:  2018-01-11

6.  Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.

Authors:  Udupi A Ramagopal; Weifeng Liu; Sarah C Garrett-Thomson; Jeffrey B Bonanno; Qingrong Yan; Mohan Srinivasan; Susan C Wong; Alasdair Bell; Shilpa Mankikar; Vangipuram S Rangan; Shrikant Deshpande; Alan J Korman; Steven C Almo
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-08       Impact factor: 11.205

7.  Treatment with retinoid X receptor agonist IRX4204 ameliorates experimental autoimmune encephalomyelitis.

Authors:  Roshantha As Chandraratna; Randolph J Noelle; Elizabeth C Nowak
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

8.  CTLA-4 expressed by FOXP3+ regulatory T cells prevents inflammatory tissue attack and not T-cell priming in arthritis.

Authors:  Katrin Klocke; Rikard Holmdahl; Kajsa Wing
Journal:  Immunology       Date:  2017-06-20       Impact factor: 7.397

9.  Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.

Authors:  Emanuela Romano; Monika Kusio-Kobialka; Periklis G Foukas; Petra Baumgaertner; Christiane Meyer; Pierluigi Ballabeni; Olivier Michielin; Benjamin Weide; Pedro Romero; Daniel E Speiser
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

Review 10.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.